A long­time Pfiz­er chief's ul­tra-qui­et biotech re-emerges with new cash and plans for the clin­ic

In Au­gust 2018, a tiny biotech spin­out from Cor­nell an­nounced they had hired for­mer high-rank­ing Pfiz­er ex­ec­u­tive Geno Ger­mano as CEO. And then they said noth­ing else. For two years. Lit­er­al­ly, the com­pa­ny, called Elu­ci­da On­col­o­gy, did not is­sue a sin­gle oth­er press re­lease un­til this past Oc­to­ber, when they hired a chief med­ical of­fi­cer.

Now, though, Elu­ci­da seems to be ready to start tak­ing the lid off their op­er­a­tions. On Tues­day at JP Mor­gan, Ger­mano walked in­vestors through the nanopar­ti­cle tech­nol­o­gy they’ve been de­vel­op­ing for can­cer. And the same day, the com­pa­ny an­nounced a new fi­nanc­ing, rais­ing $44 mil­lion in a Se­ries “A-1” round meant to pro­pel them in­to the clin­ic this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER